AbbVie

Touting their “commitment to openness,” AbbVie, Biogen and Pfizer last week launched a web-based tool giving access to results from analyses of whole exome sequencing data from 300,000 UK Biobank participants—producing “the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease,” according to a joint press release.

The initiative may also be an effort to comply with government- and Wellcome-backed Biobank requirements to share…

The state of the hunt:

Moderna’s became the second Covid-19 vaccine to receive U.S. FDA Emergency Use Authorization.
  COVAX has secured nearly 2 billion doses of vaccines but faces a “very high” failure risk, according to Reuters.
  Canada, Saudi Arabia and the United States have begun immunization campaigns using Pfizer/BioNTech’s jab.

 

Vaccines


Approved or authorized vaccines
 
The U.S. FDA granted Emergency Use Authorization (EUA…

The state of the hunt:

Novavax brought its vaccine candidate to Phase 2.
  WHO reportedly offered wealthier countries new, more flexible terms for the COVAX Facility.
  The U.S. FDA expanded the Emergency Use Authorization for Gilead’s Veklury (remdesivir).

 

Vaccines

Phase 3 candidates:
 
Pfizer and BioNTech have enrolled more than half of the 30,000 people they seek for U.S.-based Phase 3 trials of their mRNA Covid-19 vaccine candidate,…

The state of the hunt:

Serum Institute of India inked a billion-dose deal to commercialize Novavax’s vaccine candidate in LMICs.
  SII will also collaborate with the Gates Foundation and Gavi to provide 100 million doses of an eventual vaccine to LMICs at $3 per dose or less.
  J&J will supply 100 million doses of its investigational vaccine to the U.S. as part of a $1 billion contract.

 

Vaccines

Clinical trials:

BioNTech and Fosun Pharma…


The state of the hunt: 

Gavi launched an advance market commitment for Covid-19 vaccines with a $2 billion funding target. Gavi also kicked off a worldwide pooled procurement mechanism for coronavirus vaccines. CEPI announced an investment of up to $383 million in a partnership with AstraZeneca to support manufacturing of the company’s vaccine candidate for distribution by the Gavi-led procurement facility.

 

Vaccines

Existing candidates:
 
The…

Six leading pharma companies released first-quarter 2020 financial results in May, while two Japanese firms reported full-year 2019 results for fiscal years ending in March. Covid-19 dominated the reports, spurring short-term sales gains for many companies while generating longer-term uncertainty, given the unknown duration and impact of the pandemic. Ahead of the results, some analysts had drastically lowered estimates in anticipation of a slowdown in routine medical procedures.

(…


The state of the hunt: 

Moderna received U.S. FDA clearance to proceed with Phase 2 studies of its investigational vaccine, mRNA-1273, as it continues accelerating its development program. Moderna also moved up the targeted launch of Phase 3 to “early summer,” after saying as recently as April 16 that it hoped to begin in the fall. Japan’s Pharmaceuticals and Medical Devices Agency issued an emergency approval of Gilead’s remdesivir yesterday.
 

 

Vaccines

AbbVie announced this week that the U.S. Federal Trade Commission has given it the green light to move forward with its $63 billion Allergan buy, first announced last June.

As part of the agreement, the companies will offload Allergan’s late-stage gastrointestinal candidate brazikumab to AstraZeneca as well as two pancreatic replacement enzyme treatments, Zenpep and Viokace, to Nestlé.

The world saw its 1 millionth case this week as companies continued to pursue Covid-19 solutions and many moved to scale up capacity.

Essential developments included:

Vaccines

On vaccines, Johnson & Johnson pledged this week that it would bring an “affordable” Covid-19 shot to the public “on a not-for-profit basis” for emergency pandemic use. It announced it has identified a lead candidate—Ad26 SARS-CoV-2—plus two investigational “backups,” and said it has begun scaling…

As the United States eclipsed China in confirmed cases, more vaccines neared human trials and funders made over $330 million in new commitments to fight Covid-19.

The week’s noteworthy developments included:

Vaccines

On vaccines, the University of Oxford announced today that it has begun recruiting volunteers for clinical trials—set to begin in weeks—of ChAdOx1 nCov-19, its adenovirus vector-based shot.

Sanofi announced today a collaboration with Massachusetts…